Bisphosphonate treatment for secondary osteoporosis in children, youth, and young adults: a systematic review and meta-analysis
Pooled result · Lumbar spine BMD z-scoreResult — go to the resultMD 0.67 95% CI 0.37–0.97Authors' conclusion
BP treatment benefits pediatric secondary osteoporosis by improving lumbar spine BMD and BMC.
Study context
- Population
- Children, youth and young adults aged ≤ 21 years with secondary osteoporosis17 studies (15 randomized controlled trials (RCTs), 2 quasi-RCTs)
- Comparison
- Bisphosphonates vs control
- Outcome
- Lumbar spine bone mineral density (BMD) z-score
Methodological detailsPRISMA, GRADE
- PRISMA
- GRADE
Pooled result
As reported in the abstract
MD
0.67
95% CI 0.37–0.97
BPvs Control
MD 0.67 (95% CI 0.37–0.97)
Further pooled results
| Outcome | MD (g) (95% CI) | |
|---|---|---|
| Lumbar spine bone mineral content (BMC) | 2.90 (0.91–4.90) | |
| −20246Difference, g (linear scale) |
Vertebral and non-vertebral fractures
- No studies adequately powered to assess vertebral and non-vertebral fractures
Patient-reported outcomes
- No consistent results
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| AEs | 1.08 (0.94–1.23) | |
| 0.512Relative risk (log scale) |
Adverse events (AEs)
- AEs comparable between treatment and control groups
AEs, short-term periods after the first infusion
- AEs more likely in the treatment group: RR
- 2.24 (1.22, 4.11) (95% CI)
Original publication
Bisphosphonate treatment for secondary osteoporosis in children, youth, and young adults: a systematic review and meta-analysis. Osteoporos Int. Published 27 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →